Antonio

Dr. Grillo-Lopez Serves as Consultant of clinical research and regulatory strategy to the National Cancer Institute (NCI) and to several biotechnology companies.  Dr. Grillo-Lopez served as the Chief Medical Officer Emeritus of IDEC Pharmaceuticals Corporation (now Biogen Idec, Inc.). Previously, he served as Chief Medical Officer and Senior Vice President of medical and regulatory affairs of IDEC Pharmaceuticals Corporation from November 1992 to January 2001.  Prior to joining IDEC, he served as an Executive Medical Director for International Clinical Research and Development at Dupont-Merck Pharmaceuticals, was responsible for medical research worldwide, including products in the fields of oncology, immunology, cardiology, neurology and infectious disease. Until 1992, Dr. Grillo-Lopez served as Vice President, clinical therapeutics and director, clinical oncology research at Warner Lambert Company’s Parke-Davis Pharmaceutical Research Division.  In his career, he has been instrumental in the clinical development of over 25 anticancer agents including Rituxan, Zevalin, trimetrexate, deoxycoformycin, amsacrine, amsalog, brequinar, tiazofurin, eazaguanine and others. Dr. Grillo-López serves as the Chairman of Neoplastic and Autoimmune Diseases Research Institute. Dr. Grillo-Lopez served as the Chairman of Salmedix Inc.'s clinical advisory board since May 2001. He has been a Director of Onyx Pharmaceuticals, Inc. since September 2002.  Dr. Grillo-Lopez serves on the boards of directors of the National Coalition for Cancer Survivorship and the House of Puerto Rico San Diego and on the scientific advisory boards of IDEC Pharmaceuticals Corporation, SuperGen, Inc., Tragen Pharmaceuticals and the Lymphoma Research Foundation. He serves as Member of Scientific Advisory Board at Conforma Therapeutics Corporation. He served as Member of Scientific Advisory Board at Othera Pharmaceuticals, Inc. He served as Director of Salmedix Inc., since June 2002. He served as a Director at Ambit Biosciences Corporation since November 2007.  He served as Director at MMRGlobal, Inc. and Favrille, Inc. from January 2001 to January 2009. He served as Member of Clinical Advisory Board of Point Therapeutics Inc., since February 2006. He served as a Member of the Advisory Board of Attenuon, LLC. He served as Member of Scientific Advisory Board of Nereus Pharmaceuticals, Inc. Most recently, Dr. Grillo-Lopez was appointed as industry representative to the Oncology Drug Advisory Committee of the FDA. He was Associate Professor of Medicine, University of Michigan Medical School and associated with university from 1980 to 1990, and Director, Regional Medical Program in Hematology, Oncology and Blood Banking at the University of Puerto Rico.  He has authored more than 400 publications, primarily in the fields of oncology and hematology.